Daré Bioscience, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Daré Bioscience, Inc.
Bayer is paying $425m upfront to acquire KaNDy Therapeutics, whose CEO tells Scrip that the German group was always the preferred partner due to its long-standing commitment to women’s health.
Public Company Edition: ORIC’s initial public offering is the third by a drug developer in April and the 12th in 2020. Also, Pluristem garnered €50m from the European Investment Bank.
Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.
Scynexis highlights enrollment exceeding expectations in Phase III VVC trials; Daré prepares to enter Phase III to treat BV.
- Medical Devices
- Drug Delivery
- Other Names / Subsidiaries
- Cerulean Pharma Inc. (CERU)
- Dare Bioscience, Inc.
- Microchips Biotech, Inc.
- Pear Tree Pharmaceuticals, Inc. Tempo Pharmaceuticals, Inc.